Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Masumi Tachibana, Nobuhisa Kanahara, Yasunori Oda, Tadashi Hasegawa, Atsushi Kimura, Masaomi Iyo
STUDY OBJECTIVES: Although novel hypnotics have recently emerged, there are currently no data comparing the clinical potency of benzodiazepine receptor agonists (BZRAs) and novel hypnotics, or the effectiveness of different methods of switching between them. This study examined how novel hypnotics might help reduce BZRA use in real-world practice. METHODS: 289 patients with psychiatric disorders who took BZRAs for over 1 year before switching to either of two dual-orexin receptor antagonists (DORAs) (suvorexant (SUV) or lemborexant (LEM)) or a melatonin receptor agonist (ramelteon (RMT)) were enrolled...
December 8, 2023: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
#2
JOURNAL ARTICLE
Weizhen Wu, Junning Zhang, Yizhuo Qiao, Lijiang Ren, Zhe Chen, Yan Fu, Zhixu Yang
Benzodiazepine hypnotics' effects on glucose metabolism are seldom reported, and the association between long-term (≥4 weeks) benzodiazepine usage and prediabetes has not been studied. This study was aimed to investigate the association between benzodiazepine hypnotic usage for ≥ 3 months and the prevalence of prediabetes. We analyzed cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) during 2005 to 2008, selecting adult participants without diabetes who used benzodiazepine hypnotics for at least 3 months or did not take any hypnotics...
November 10, 2023: Medicine (Baltimore)
#3
JOURNAL ARTICLE
Santiago Galán, Rocío de la Vega, Rosa Esteve, Alicia E López-Martínez, Mariano Fernández Baena, Carmen Ramírez-Maestre
BACKGROUND: Opioids are being prescribed widely, and increasingly, for the treatment of chronic non-cancer pain (CNCP). However, several side effects are associated with mid- and long-term opioid use and, for certain patients, with the risk of problematic opioid use. The aim of this study is to know the perception of the physicians about which variables could be associated with increased risk of patients with CNCP developing a problem of abuse or misuse of the prescribed opioid medication...
2023: Front Pain Res (Lausanne)
#4
RANDOMIZED CONTROLLED TRIAL
Amit Kosto, Danielle Lev, Nadav Reiss, Tehilah Meged-Book, Yan Press
BACKGROUND: Treating insomnia with hypnotic drugs in elderly patients has many adverse effects. This study aims to assess the effect of two discontinuation methods of hypnotic drugs during acute hospitalization. METHODS: We conducted an open-label randomized controlled trial that included participants aged 60 and above taking benzodiazepines or Z-Drugs for at least 3 months as a treatment for insomnia and were admitted to the hospital. In the prospective arm, patients were randomly assigned into two intervention groups...
October 2023: International Journal of Geriatric Psychiatry
#5
JOURNAL ARTICLE
Florian Monney, Victoria Ando, Marie Méan
Benzodiazepines are among the most frequently prescribed medications in Switzerland, particularly in the elderly. Due to their unfavourable side effect profile, especially in the elderly population, this class of medication should not be prescribed for the treatment of insomnia or non-refractory anxiety disorders. A gradual withdrawal procedure, which is safe and effective according to the literature, should be offered to the patient taking such medication, with adequate monitoring of withdrawal symptoms. This procedure should, in principle, be performed in an outpatient setting but may be initiated in the hospital after discussion with the patient and the primary care physician...
September 13, 2023: Revue Médicale Suisse
#6
Atsuhiro Kitaura, Shinichi Hamasaki, Hiroatsu Sakamoto, Shota Tsukimoto, Yasufumi Nakajima
We report the inadequate efficacy of remimazolam in two patients undergoing long-term benzodiazepine analog therapy. Remimazolam is a recently developed ultrashort-acting benzodiazepine. It is primarily used as an anesthetic in surgical procedures, as it has minimal effect on cardiac function and antagonists are available. It is expected to become more widely used in the future. On the other hand, similar to other benzodiazepines, benzodiazepine tolerance can also pose a challenge with remimazolam. Herein, we report two cases who were taking long-term oral benzodiazepine analogs...
July 2023: Curēus
#7
JOURNAL ARTICLE
Esther G Teverovsky, Ariel Gildengers, Xinhui Ran, Erin Jacobsen, Chung-Chou H Chang, Mary Ganguli
OBJECTIVES: Older adults commonly take benzodiazepines (BZDs) that may have long-term adverse cognitive effects. We investigated whether BZD use was related to developing mild cognitive impairment (MCI) or dementia in cognitively normal older adults in the community. SETTING/PARTICIPANTS: A population-based cohort ( n = 1959) of adults aged 65 and over, recruited from communities of low socioeconomic status. MEASUREMENTS: BZD use, Clinical Dementia Rating (CDR), anxiety symptoms, depression symptoms, sleep difficulties, and APOE genotype...
May 26, 2023: International Psychogeriatrics
#8
JOURNAL ARTICLE
Anna Castelnovo, Silvia Miano, Raffaele Ferri, Alberto Raggi, Michelangelo Maestri, Valentina Bottasini, Matteo Anelli, Marco Zucconi, Vincenza Castronovo, Luigi Ferini-Strambi, Mauro Manconi
Benzodiazepine (BDZ) misuse is a growing health problem, with 1-2% of patients under BDZ treatment meeting the criteria for use disorder or dependence. Although BDZ addiction potential has been known for decades, much remains unknown its effects on brain functions. The aim of this study was to assess the neuropsychological and neurophysiological profile of a group of chronic insomniacs taking long-term high doses of benzodiazepine. We recruited 17 consecutive patients admitted to our third-level Sleep Medicine Unit for drug discontinuation (7 males, mean age 49...
February 21, 2023: Brain Sciences
#9
JOURNAL ARTICLE
Kazumaro Okino, Hirohisa Suzuki, Hiroi Tomioka, Kenji Sanada, Keita Kawai, Akira Iwanami, Atsuko Inamoto
BACKGROUND: Although gamma-aminobutyric acid-benzodiazepine (GABA-BZ) receptor agonists are used to treat insomnia, their long-term or high-dosage use causes adverse events. Nevertheless, evidence regarding the discontinuation and replacement of GABA-BZ receptor agonists with alternative agents is lacking. Suvorexant (SUX), an existing orexin receptor antagonist, is effective in preventing nocturnal awakening in 70-75% of patients with insomnia. METHODS: The novel dual orexin receptor antagonist lemborexant (LEM) has fewer adverse effects than GABA-BZ receptor agonists...
March 24, 2023: Human Psychopharmacology
#10
JOURNAL ARTICLE
Michael A Cucciare, Traci H Abraham, Lakiesha Kemp, Penny White, Kathy Marchant, Hildi J Hagedorn, Keith Humphreys
BACKGROUND: Long-term dependence on prescribed benzodiazepines is a public health problem. Eliminating Medications Through Patient Ownership of End Results (EMPOWER) is a promising self-management intervention, delivered directly to patients as a printed booklet, that is effective in promoting benzodiazepine reduction and cessation in older adults. EMPOWER has high potential to benefit large health care systems such as the US Veterans Health Administration (VHA), which cares for many veterans who use benzodiazepines for extended periods...
September 19, 2022: Journal of Medical Internet Research
#11
JOURNAL ARTICLE
Michael A Cucciare, Hildi J Hagedorn, Mark Bounthavong, Traci H Abraham, Carolyn J Greene, Xiaotong Han, Lakiesha Kemp, Kathy Marchant, Penny White, Keith Humphreys
Background: Long-term benzodiazepine dependence carries significant health risks which might be reduced with low-cost patient self-management interventions. A booklet version of one such intervention (Eliminating Medications Through Patient Ownership of End Results; EMPOWER) proved effective in a Canadian clinical trial with older adults. Digitizing such an intervention for electronic delivery and tailoring it to different populations could expand its reach. Accordingly, this article describes the protocol for a randomized controlled trial to test the effectiveness of an electronically-delivered, direct-to-patient benzodiazepine cessation intervention tailored to U...
October 2022: Contemporary Clinical Trials Communications
#12
JOURNAL ARTICLE
Akise Umakoshi, Masahiro Takeshima, Yu Itoh, Mari Yamamoto, Nana Shibata, Masaya Ogasawara, Naoko Ayabe, Kazuo Mishima
AIM: It is controversial whether psychotic features are a risk factor for relapse in patients with electroconvulsive therapy-responsive major depressive disorder. A recent study reported that benzodiazepine receptor agonists reduce relapse of psychotic depression. As long-term use of these agonists may induce dependence, further research is required. We examined whether psychotic features are associated with rehospitalization in electroconvulsive therapy-responsive major depressive disorder patients...
July 22, 2022: Neuropsychopharmacology Reports
#13
JOURNAL ARTICLE
Anisha Soni, Arun Thiyagarajan, Joanne Reeve
BACKGROUND AND AIMS: A total of 2.4 million adults in England were dispensed a benzodiazepine or Z-drug (BZRA) in 2017/18, and more than 250 000 patients in the UK take BZRAs beyond the recommended duration. Deprescribing is a clinician-guided process of withdrawing inappropriate drugs. This review aimed to evaluate the evidence base supporting the feasibility and clinical effectiveness of all forms of deprescribing initiatives used to discontinue long-term (≥ 4 weeks) BZRAs...
January 2023: Addiction
#14
JOURNAL ARTICLE
Charlotte Archer, Stephanie J MacNeill, Becky Mars, Katrina Turner, David Kessler, Nicola Wiles
BACKGROUND: Little is known about trends in prescribing of anxiolytics (antidepressants, benzodiazepines, beta-blockers, anticonvulsants, and antipsychotics) for treatment of anxiety. Several changes may have affected prescribing in recent years, including changes in clinical guidance. AIM: To examine trends in prescribing for anxiety in UK primary care between 2003 and 2018. DESIGN AND SETTING: A population-based cohort study using Clinical Practice Research Datalink (CPRD) data...
January 31, 2022: British Journal of General Practice
#15
Pezhman Hadinezhad, Seyed Hamzeh Hosseini
Background: Zolpidem is a non-benzodiazepine drug, approved by FDA for sleep induction. Zolpidem is thought to be a safer drug than benzodiazepines (BZD) because of no evidence of abuse or dependence potential, but several case reports of zolpidem abuse and dependence have been published along with a small number of cases demonstrating seizures after sudden zolpidem withdrawal. Case presentation: A 32-year-old unmarried woman suffering from major depressive disorder had been taking zolpidem for insomnia for more than 1 year...
2021: Caspian Journal of Internal Medicine
#16
JOURNAL ARTICLE
Darías Holgado, Agustín Manresa-Rocamora, Lorenzo Zamboni, Fabio Lugoboni, Ana María Peiró, Thomas Zandonai
The use of benzodiazepines among athletes is a new and growing phenomenon according to the recent case reports published. Therefore, there is an urgent need to identify if there is rationale for the use of benzodiazepines and its effects on exercise. This review aims to provide an overview of the effects of benzodiazepine in exercise among healthy adult participants and if they might have an additional ergogenic or ergolytic effect. Electronic searches were conducted in Pubmed, Scopus and Web of Science databases up to December 2020...
July 2022: Journal of Addictive Diseases
#17
JOURNAL ARTICLE
Paul S Haber, Benjamin C Riordan, Daniel T Winter, Liz Barrett, John Saunders, Leanne Hides, Matthew Gullo, Victoria Manning, Carolyn A Day, Yvonne Bonomo, Lucinda Burns, Robert Assan, Ken Curry, Julie Mooney-Somers, Apo Demirkol, Lauren Monds, Mike McDonough, Andrew J Baillie, Paul Clark, Alison Ritter, Catherine Quinn, John Cunningham, Nicholas Lintzeris, Susan Rombouts, Michael Savic, Amanda Norman, Sharon Reid, Delyse Hutchinson, Catherine Zheng, Yasmine Iese, Nicola Black, Brian Draper, Nicole Ridley, Linda Gowing, Lexine Stapinski, Belaynew Taye, Kari Lancaster, Daniel Stjepanović, Frances Kay-Lambkin, Nazila Jamshidi, Dan Lubman, Adam Pastor, Natalie White, Scott Wilson, Alison L Jaworski, Sonja Memedovic, Warren Logge, Katherine Mills, Kate Seear, Bradley Freeburn, Toby Lea, Adrienne Withall, Christina Marel, John Boffa, Amanda Roxburgh, Gemma Purcell-Khodr, Michael Doyle, Kate Conigrave, Maree Teesson, Kerryn Butler, Jason Connor, Kirsten C Morley
OF RECOMMENDATIONS AND LEVELS OF EVIDENCE: Chapter 2: Screening and assessment for unhealthy alcohol use Screening Screening for unhealthy alcohol use and appropriate interventions should be implemented in general practice (Level A), hospitals (Level B), emergency departments and community health and welfare settings (Level C). Quantity-frequency measures can detect consumption that exceeds levels in the current Australian guidelines (Level B). The Alcohol Use Disorders Identification Test (AUDIT) is the most effective screening tool and is recommended for use in primary care and hospital settings...
October 4, 2021: Medical Journal of Australia
#18
JOURNAL ARTICLE
Rüdiger Holzbach, Petra Hunold, Frank Konert
OBJECTIVE: The Lippstädter Benzo-Check is intended to motivate those affected by unwanted effects of Benzodiazepines and Z-drugs. This study serves as the first check whether the Lippstädter Benzo-Check adequately recorded the symptoms of longterm-use before the withdrawal and, on the other hand, a depressive control group without taking the corresponding drugs unremarkable values achieved. METHODS: 101 inpatient withdrawal patients with dependency on Benzodiazepines or Z-drugs and 154 day clinic patients without benzodiazepines or Z-drugs completed the Lippstädter Benzo-Check at the beginning of treatment...
November 2021: Fortschritte der Neurologie-Psychiatrie
#19
JOURNAL ARTICLE
Ben Maudlin, Stephen B Gibson, Arun Aggarwal
BACKGROUND: Chronic non-malignant pain is a disabling condition that results in a reduction in function and quality of life when inadequately managed. Sublingual ketamine has been shown to be efficacious for use in chronic pain. Despite its use for decades in chronic non-malignant pain, there is no published long-term data on safety, side-effects or adverse drug reactions. AIM: The aim of this case-series is to provide the initial evidence for safety and efficacy in this patient group...
September 2022: Internal Medicine Journal
#20
JOURNAL ARTICLE
Eric B Segal, Daniel Tarquinio, Ian Miller, James W Wheless, Dennis Dlugos, Victor Biton, Gregory D Cascino, Jay Desai, R Edward Hogan, Kore Liow, Michael R Sperling, Blanca Vazquez, David F Cook, Adrian L Rabinowicz, Enrique Carrazana
OBJECTIVE: Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration. This interim analysis evaluated the safety profile of diazepam nasal spray in patients with and without concomitant use of benzodiazepines, with use of a second dose for a seizure cluster as a proxy for effectiveness. METHODS: A long-term, phase 3, open-label safety study enrolled patients with epilepsy who had seizures despite a stable antiseizure medication regimen...
May 4, 2021: Epilepsia
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
